This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Dopamine agonist induced adverse effects

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

These include:

  • nausea
  • dizziness and postural hypotension
  • these adverse effects are dose-related - they can be limited by increasing the dose slowly and often reduce with continued therapy

Other side effects include:

  • neuropsychiatric toxicity e.g. vivid dreams, hallucinations, hypersexuality, delusions - often associated with paranoia, confusion
  • neuropsychiatric toxicity is commoner in older patients, those with underly cognitive deficits, those who have suffered neuropsychiatric adverse reactions from other antiparkinsonian medication; also these side effects are more common when other antiparkinsonian medication and dopamine agonists are used concomitantly
  • neuropsychiatric side effects are not strongly dose - related; however reduction of the dose of dopamine agonist sometimes improves neuropsychiatric toxicity but may result in aggravation of parkinsonism. A reduction in the dose of other antiparkinsonian drugs, especially anticholinergics, may help
  • uncommon idiosyncratic side-effects include inflammatory pleuro-pulmonary disease

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.